

BAA 14-003 Call 0012 Industry Questions

| Question # | Reference | Contractor's Questions | Government Responses |
|------------|--|---|--|
| 1 | Reference BAA 14-003/call 0012 page 6/7 Section 12 | Section 12 makes reference to a 'company to company agreement attached to this BAA call'. I see no attachments other than the call. Is an attachment for the 'company to company agreement' supposed to be present, or is there a different area that I need to visit to access the 'company to company agreement'? | There is no attachment. Each interested party will need to reach out to the designated POC listed in the solicitation to initiate a company to company agreement. See language correction in section 12. |
| 2 | Reference BAA 14-003/call 0012 page 5 Section 10 | Section 12 makes reference to submitting 'Full Proposals in accordance with BAA 14-003, Section 5.4 - Format and Content of Full Proposals. Can a link or website address be provided for this BAA? | See section 3 of the solicitation. |
| 3 | BAA 14-003 / Call 0012, page 1, Section 3, third paragraph AND page 5, Section 10 | Section 3 of Call 0012 indicates that the Full Proposal is limited to 30 pages; however, in section 10, it indicates that the Full Proposal should be submitted in accordance with BAA 14-003 Section 5.4, which says that the Full Proposal is limited to 40 pages (Volume 1: 30 pages, Volume 2: 10 pages). Can you please clarify? | Section 3 states: "This Call will consist of the solicitation, receipt, and evaluation of a Full Proposal, limited to 30 pages, excluding the Formal Transmittal Letter, Cover Page, Summary of Costs and Related Information, Table of Contents and resumes/biographical information for proposed performers." Therefore: Volume I – Technical, 30 pages Volume II – Cost, 10 pages |
| 4 | BAA 14-003/call0012, page 4 section 4.1.2.2. Technical Topic 2: Generation of live –vectored ASFV express constructs | Will contractor be allowed/offered opportunity to conduct pig studies to validate immunogenicity of the expression constructs? This will allow involved of students/postdocs: generation of data for publication is critical for their training. | Yes, proof of concept swine studies, without virulent ASF virus challenge, can be offered to validate immunogenicity of the live-vectored ASFV constructs. |

| | | | |
|---|--|--|--|
| 5 | BAA 14-003/call0012, page 3, section 4.1.2.1 Technical Topic 1: Generation of recombinant antigens | What is the estimated amount of antigen required as a deliverable? The term “sufficient quantities” is too general (cost will depend on amount to be generated.) Is there a preferred concentration and buffer/sterile or non-sterile? | A minimum of 1.0 mg of recombinant protein for each ASFV target selected. If using Bacmid system, a minimum of 2 mg of recombinant plasmid for each ASFV target selected. |
| 6 | BAA 14-003/Call 0012, page 3, section 4.1.2.1. technical topic 1, second paragraph first bullet point “Using the 12 published annotated ASFV genomes...” | Not clear what “published” means. In looking through GenBank, there appear to be only 9 full-length annotated ASFV genome sequences. Could you provide a list of the 12 annotated ASFV sequences referred to in the BAA?, i.e. provide the 12 GenBank accession numbers. Or could you provide the resources for searching the published sequences? | The list of annotated ASFV sequences can be found at: http://athena.bioc.uvic.ca/organisms/dsdna-viruses/asfarviridae/ |